fda drug safety communication naion semaglutide 2025 GLP-1 RAs and NAION: New study in AJO 📣As of March 19, 2025,

Week 48: Phase 2 Results Kept Building At 48 weeks in the same Phase 2 trial, the least-squares mean body-weight change was 17.1% in the combined 4 mg group, 22.8% in the combined 8 mg group, and 24.2% in the 12 mg group, compared with 2.1% for placebo

As a result, individuals may experience gradual and consistent weight loss, leading to improved overall health and quality of life

Feed Your Gut Cells & Support Natural GLP-1 Pathways*

Retatrutide delays gastric emptying (phase 1b / human data)

She reached a peak weight of 100kg about a year ago, but has since lost 25kg

Together, these findings demonstrate CBT-Is ability to enhance workplace performance, reduce missed workdays, and deliver cost savings, thereby making it a practical and effective tool for organizations aiming to improve employee well-being and productivity